文献速递脊柱脊髓外科

CaO-SiO2-P2O5-B2O3生物活性玻璃陶瓷间隔器在后路腰椎椎间融合术中与聚醚醚酮融合器比较的可行性与安全性:一项前瞻性随机对照试验

Feasibility and safety of a CaO-SiO2-P2O5-B2O3 bioactive glass ceramic spacer in posterior lumbar interbody fusion compared with polyetheretherketone cage: a prospective randomized controlled trial.
PubMed 文献 · Acta Neurochir (Wien) · 2022-12-06

54例因腰椎退行性疾病需行单节段或双节段后路腰椎椎间融合术的患者随机接受BGS-7间隔器或PEEK融合器。术后12个月融合率BGS-7组77.8% vs PEEK组81.0%,无显著差异(p=0.807),非劣效性结论不确定;BGS-7组融合器周围下沉显著更低,但需考虑间隔器骨折和移位的安全性问题。

要点

  • 12个月融合率BGS-7组77.8% vs PEEK组81.0%,无显著差异(p=0.807),非劣效性结论不确定。
  • VAS、ODI、EQ-5D和painDETECT评分在3、6、12个月随访时均无显著干预效应。
  • BGS-7组融合器周围下沉显著低于PEEK组,但需考虑间隔器骨折和移位的安全性问题。

核心结论

  • 本试验发现BGS-7间隔器与PEEK融合器在后路腰椎椎间融合术中的融合率和临床影像学结果相似,但非劣效性结论不确定。
  • 必须考虑BGS-7间隔器骨折和移位的安全性问题,BGS-7间隔器设计在进一步临床使用前应予以修改。

研究设计与样本

  • 前瞻性随机对照试验,54例因腰椎退行性疾病需行单节段或双节段后路腰椎椎间融合术的参与者随机分配至BGS-7间隔器组或PEEK融合器组。

主要发现

  • 12个月融合率BGS-7间隔器组77.8% vs PEEK融合器组81.0%,无显著差异(p=0.807)。
  • 线性混合模型显示VAS、ODI、EQ-5D和painDETECT评分在3、6、12个月随访时均无显著干预效应。
  • 骨溶解程度和间隔器移位方面组间无显著差异。
  • BGS-7间隔器组融合器周围下沉显著低于PEEK融合器组。

临床怎么用

  • 作者认为BGS-7间隔器设计在后路腰椎椎间融合手术进一步临床使用前应予以修改。

局限性

  • 非劣效性结论不确定。
  • 必须考虑BGS-7间隔器骨折和移位的安全性问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The CaO-SiO2-P2O5-B2O3 glass-ceramic (BGS-7) spacer is a recently developed spacer that shows chemical bonding to bone with high mechanical stability. Further, this spacer achieves similar results to those of titanium cages. However, evidence regarding the advantages of the BGS-7 spacer is weak compared to polyetheretherketone (PEEK) cage. A randomized controlled trial is therefore warranted. The purpose of this study was to compare the radiographic and clinical efficacies and safety of the BGS-7 spacer compared to those of the PEEK cage in patients who underwent posterior lumbar interbody fusion (PLIF). METHODS: The 54 participants who required one- or two-level PLIF due to lumbar degenerative disorders were randomly assigned to receive a BGS-7 spacer or PEEK cage. Visual analog scale (VAS), Oswestry Disability Index (ODI), European Quality of Life-5 Dimensions (EQ-5D), and painDETECT score were evaluated before surgery and at 3, 6, and 12 months after surgery. The fusion rate, degree of osteolysis, cage migration, and subsidence around the cage (spacer) were evaluated on computer tomography (CT) images at 12 months after surgery. RESULTS: The 12-month fusion rates were 77.8% in the BGS-7 spacer group and 81.0% in the PEEK cage group, with no significant difference (p = 0.807). The result regarding the non-inferiority of BGS-7 spacer was inconclusive. The linear mixed model showed no significant intervention effect in VAS, ODI, EQ-5D, and painDETECT score at the 3-, 6-, or 12-month follow-up. In addition, we found no significant between-group differences in the extent of osteolysis, spacer migration. However, the subsidence around the cage was significantly lower in the BGS-7 spacer group. CONCLUSIONS: This trial found similar fusion rates, and clinicoradiographic outcomes between the BGS-7 spacer and PEEK cage for PLIF. However, the non-inferiority was inconclusive. Safety concerns regarding fracture and migration of the BGS-7 spacer must be considered. Thus, the BGS-7 spacer design for PLIF surgery should be modified before further clinical use.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Kwon BT, Kim HJ, Lee S, et al. Feasibility and safety of a CaO-SiO2-P2O5-B2O3 bioactive glass ceramic spacer in posterior lumbar interbody fusion compared with polyetheretherketone cage: a prospective randomized controlled trial. Acta Neurochir (Wien). 2022. PMID: 36471204. doi:10.1007/s00701-022-05429-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。